PROCTOZONE-HC hydrocortisone 2.5% 25 mg/g Cream
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- It's designed to calm down inflammation — so the redness, swelling, and itching that come with conditions like eczema should ease up, usually within a few days of consistent use. I...
- What exactly is this cream supposed to do for my skin?
- That's a really important question. Hydrocortisone is generally meant for short courses — typically a few weeks. Long-term or widespread use can cause side effects like skin thinni...
- How long can I keep using it? Is it okay to use every day long-term?
Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 936JST6JCN
Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
-
UNII 97C5T2UQ7J
Cholesterol is a fatty substance found naturally in animal tissues. In medications, it's used as an ingredient in liposomal formulations and lipid-based drug delivery systems to help encapsulate and stabilize active drugs for better absorption.
-
UNII 230OU9XXE4
A waxy substance made from glycerin and stearic acid that acts as an emulsifier to blend oily and watery ingredients together. It also helps thicken and stabilize the medicine's texture.
-
UNII 0RE8K4LNJS
Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
-
UNII A2I8C7HI9T
Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
-
UNII 13A4J4NH9I
A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
-
UNII CAL22UVI4M
A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII Z8IX2SC1OH
Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
-
UNII X045WJ989B
Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
-
UNII NVZ4I0H58X
A waxy substance made from sorbitol and stearic acid. It acts as an emulsifier and stabilizer, helping keep oil and water mixed together and preventing separation in the medicine.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
12 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.235 | $7.05 / 30 g |
| Medicaid paysCMS SDUD · 12 mo | $0.5064 | $15.19 / 30 g |
| Medicare drug plans payPart D · Q2 2026 | $0.4620 | $13.86 / 30 g |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Hydrocortisone 25 mg/g 00168-0080-16 | E. | 454 g | $0.109 | AT | Availability likely | save 54% |
| Hydrocortisone 25 mg/g 00472-0337-20 | Actavis | 1 tube | $0.125 | — | Discontinued | save 47% |
| Hydrocortisone 25 mg/g 45802-0004-02 | Padagis | 1 tube | $0.126 | AT | Availability likely | save 47% |
| Hydrocortisone 25 mg/g 62559-0431-30 | ANI | 1 tube | $0.235 | AT | Availability likely | — |
| Proctozone-Hc 25 mg/gthis 64980-0324-30 | Rising | 1 tube | $0.235 | AT | Availability likely | — |
| Procto-Med HC 25 mg/g 69315-0312-28 | Leading | 1 tube | $0.235 | AT | Availability likely | — |
| Proctosol-HC 25 mg/g 10631-0407-01 | Sun | 1 tube | $0.698 | AT | Availability likely | +197% |
| Alacort 25 mg/g 00316-0128-16 | Crown | 454 g | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 00316-0193-16 | Crown | 1 jar | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 50090-0244-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 50090-0350-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 50090-2452-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 50090-5999-00 | A-S | 1 tube | — | — | FDA listed | — |
| Hydrocortisone 25 mg/g 51672-3003-00 | Sun | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 61919-0364-30 | DIRECT | 30 g | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 63187-0480-20 | Proficient | 1 tube | — | — | FDA listed | — |
| Hydrocortisone 25 mg/g 63629-1952-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Proctozone-Hc 25 mg/g 63629-2396-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 63629-8666-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 63629-8667-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Proctozone-Hc 25 mg/g 63629-8847-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Anusol HC 25 mg/g 65649-0401-30 | Salix | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 66267-0967-01 | NuCare | 30 g | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 68071-2233-01 | NuCare | 1 tube | — | AT | FDA listed | — |
| Procto-Med HC 25 mg/g 68071-3968-01 | NuCare | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 68071-4511-02 | NuCare | 20 g | — | — | FDA listed | — |
| Proctozone-Hc 25 mg/g 68788-7091-03 | Preferred | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 68788-8302-03 | Preferred | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 68788-8583-02 | Preferred | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 68788-9922-03 | Preferred | 1 tube | — | AT | Discontinued | — |
| Hydrocortisone 25 mg/g 70518-3078-00 | REMEDYREPACK | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 71335-2954-01 | Bryant | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 72162-1382-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 72162-1764-03 | Bryant | 1 tube | — | AT | FDA listed | — |
| Proctozone-Hc 25 mg/g 72162-1805-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Proctosol-HC 25 mg/g 72162-2165-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone Cream 25 mg/g 72189-0554-28 | Direct_Rx | 20 g | — | AT | FDA listed | — |
| Hydrocortisone Cream 25 mg/g 72189-0625-30 | Direct_Rx | 1 g | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 82804-0135-28 | Proficient | 1 tube | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 85766-0081-30 | Sportpharm | 30 g | — | AT | FDA listed | — |
| Hydrocortisone 25 mg/g 85766-0085-30 | Sportpharm | 1 tube | — | AT | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 64980-0324-30 You're viewing this | 1 TUBE in 1 CARTON (64980-324-30) / 30 g in 1 TUBE | 2015-08-03 | Active |
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
⛔ Contraindications ▾
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS contact Rising Pharmaceuticals, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects: Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.
Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.
🆘 Overdosage ▾
OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic, and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.
(see DOSAGE AND ADMINISTRATION. ) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Some of the topical corticosteroids and their metabolites are also excreted into the bile.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED PROCTOZONE-HC ® 2.5% (Hydrocortisone Cream, USP 2.5%) Tubes containing 30 g (1.1 oz) NDC 64980-324-30 Storage Keep tightly closed. Store at 20° – 25° C (68° – 77° F) excursion permitted to 15° – 30° C (59° – 86° F) [See USP Controlled Room Temperature]. Keep out of the reach of children. Distributed by: Manufactured by: Rising Pharmaceuticals, Inc. Lyne Laboratories, Inc. East Brunswick, NJ 08816 Brockton, MA 02301 R4-02/23 PIR32430-01
📦 Storage and Handling ▾
Storage Keep tightly closed. Store at 20° – 25° C (68° – 77° F) excursion permitted to 15° – 30° C (59° – 86° F) [See USP Controlled Room Temperature]. Keep out of the reach of children.
📋 Description ▾
DESCRIPTION Each gram of Proctozone-HC ® (Hydrocortisone Cream, USP 2.5%) contains 25 mg of hydrocortisone in a water-washable base of purified water, propylene glycol, glyceryl monostearate SE, cholesterol, isopropyl myristate, polysorbate 60, cetyl alcohol, sorbitan monostearate, polyoxyl 40 stearate, sorbic acid, methylparaben, and propylparaben. Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11β)-] with the molecular formula (C 21 H 30 O 5 ) and is represented by the following structural formula: Its molecular weight is 362.46 and its CAS Registry Number is 50-23-7.
The topical corticosteroids, including hydrocortisone, constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. structure
💬 Information for Patients ▾
Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. Patients should report any signs of local adverse reactions, especially under occlusive dressing.
Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.